Logo image of AKBA

AKEBIA THERAPEUTICS INC (AKBA) Stock Fundamental Analysis

NASDAQ:AKBA - Nasdaq - US00972D1054 - Common Stock - Currency: USD

2.45  +0.06 (+2.51%)

After market: 2.43 -0.02 (-0.82%)

Fundamental Rating

2

Taking everything into account, AKBA scores 2 out of 10 in our fundamental rating. AKBA was compared to 566 industry peers in the Biotechnology industry. AKBA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AKBA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

AKBA had negative earnings in the past year.
AKBA had a negative operating cash flow in the past year.
AKBA had negative earnings in each of the past 5 years.
AKBA had a negative operating cash flow in each of the past 5 years.
AKBA Yearly Net Income VS EBIT VS OCF VS FCFAKBA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

AKBA has a Return On Assets of -31.45%. This is in the better half of the industry: AKBA outperforms 65.19% of its industry peers.
Industry RankSector Rank
ROA -31.45%
ROE N/A
ROIC N/A
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKBA Yearly ROA, ROE, ROICAKBA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

AKBA has a better Gross Margin (83.67%) than 86.40% of its industry peers.
In the last couple of years the Gross Margin of AKBA has grown nicely.
The Profit Margin and Operating Margin are not available for AKBA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
AKBA Yearly Profit, Operating, Gross MarginsAKBA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

AKBA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AKBA has been increased compared to 1 year ago.
AKBA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AKBA has a worse debt to assets ratio.
AKBA Yearly Shares OutstandingAKBA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
AKBA Yearly Total Debt VS Total AssetsAKBA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -9.11, we must say that AKBA is in the distress zone and has some risk of bankruptcy.
AKBA has a Altman-Z score of -9.11. This is in the lower half of the industry: AKBA underperforms 71.91% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.11
ROIC/WACCN/A
WACC10.27%
AKBA Yearly LT Debt VS Equity VS FCFAKBA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

AKBA has a Current Ratio of 1.41. This is a normal value and indicates that AKBA is financially healthy and should not expect problems in meeting its short term obligations.
AKBA's Current ratio of 1.41 is on the low side compared to the rest of the industry. AKBA is outperformed by 83.57% of its industry peers.
AKBA has a Quick Ratio of 1.21. This is a normal value and indicates that AKBA is financially healthy and should not expect problems in meeting its short term obligations.
AKBA has a worse Quick ratio (1.21) than 84.45% of its industry peers.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 1.21
AKBA Yearly Current Assets VS Current LiabilitesAKBA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for AKBA have decreased strongly by -17.86% in the last year.
AKBA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.69%.
The Revenue for AKBA have been decreasing by -13.72% on average. This is quite bad
EPS 1Y (TTM)-17.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3356.25%
Revenue 1Y (TTM)-17.69%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%-17.26%

3.2 Future

The Earnings Per Share is expected to grow by 52.37% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 35.60% on average over the next years. This is a very strong growth
EPS Next Y40.5%
EPS Next 2Y39.22%
EPS Next 3Y34.87%
EPS Next 5Y52.37%
Revenue Next Year27.37%
Revenue Next 2Y35.07%
Revenue Next 3Y34.13%
Revenue Next 5Y35.6%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AKBA Yearly Revenue VS EstimatesAKBA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
AKBA Yearly EPS VS EstimatesAKBA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AKBA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKBA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKBA Price Earnings VS Forward Price EarningsAKBA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKBA Per share dataAKBA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

AKBA's earnings are expected to grow with 34.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.22%
EPS Next 3Y34.87%

More info and screens

0

5. Dividend

5.1 Amount

AKBA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKEBIA THERAPEUTICS INC

NASDAQ:AKBA (5/2/2025, 7:12:13 PM)

After market: 2.43 -0.02 (-0.82%)

2.45

+0.06 (+2.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2025-03-13/bmo
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners28.67%
Inst Owner Change0.04%
Ins Owners2.6%
Ins Owner Change7.7%
Market Cap612.13M
Analysts84.44
Price Target7.52 (206.94%)
Short Float %7.7%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-38.68%
Min EPS beat(2)-54.81%
Max EPS beat(2)-22.55%
EPS beat(4)1
Avg EPS beat(4)-16.49%
Min EPS beat(4)-54.81%
Max EPS beat(4)26.47%
EPS beat(8)4
Avg EPS beat(8)-10.63%
EPS beat(12)6
Avg EPS beat(12)5.31%
EPS beat(16)6
Avg EPS beat(16)-4.33%
Revenue beat(2)1
Avg Revenue beat(2)2.25%
Min Revenue beat(2)-17.55%
Max Revenue beat(2)22.05%
Revenue beat(4)1
Avg Revenue beat(4)-9.9%
Min Revenue beat(4)-30.64%
Max Revenue beat(4)22.05%
Revenue beat(8)1
Avg Revenue beat(8)-9.6%
Revenue beat(12)5
Avg Revenue beat(12)10.35%
Revenue beat(16)6
Avg Revenue beat(16)7.62%
PT rev (1m)-5.85%
PT rev (3m)34.09%
EPS NQ rev (1m)15.62%
EPS NQ rev (3m)10%
EPS NY rev (1m)12.5%
EPS NY rev (3m)-42.59%
Revenue NQ rev (1m)1.14%
Revenue NQ rev (3m)6.88%
Revenue NY rev (1m)6.75%
Revenue NY rev (3m)-0.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.82
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.64
BVpS-0.2
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.45%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.67%
FCFM N/A
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
F-Score3
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.09%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.41
Quick Ratio 1.21
Altman-Z -9.11
F-Score3
WACC10.27%
ROIC/WACCN/A
Cap/Depr(3y)0.13%
Cap/Depr(5y)0.3%
Cap/Sales(3y)0.02%
Cap/Sales(5y)0.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3356.25%
EPS Next Y40.5%
EPS Next 2Y39.22%
EPS Next 3Y34.87%
EPS Next 5Y52.37%
Revenue 1Y (TTM)-17.69%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%-17.26%
Revenue Next Year27.37%
Revenue Next 2Y35.07%
Revenue Next 3Y34.13%
Revenue Next 5Y35.6%
EBIT growth 1Y-1.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-74.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.88%
OCF growth 3YN/A
OCF growth 5YN/A